Literature DB >> 9142207

Orbital rhabdomyosarcomas and related tumors in childhood: relationship of morphology to prognosis--an Intergroup Rhabdomyosarcoma study.

R Kodet1, W A Newton, A B Hamoudi, L Asmar, M D Wharam, H M Maurer.   

Abstract

Children and adolescents who develop rhabdomyosarcoma (RMS) and related sarcomas in the orbit and treated on Intergroup Rhabdomyosarcoma protocols have had an extremely high cure rate. This study evaluates the possible relationship between their tumor morphologic subtypes and this high cure rate. The histology of tumors was re-reviewed from 229 of the 264 patients with tumors of the orbit, conjunctiva, and eyelids treated on Intergroup Rhabdomyosarcoma Studies (IRS I, II, III, and IV pilot protocols, and followed through July, 1992. Immunohistochemistry was applied in selected cases. Clinical correlations were done on all 264 cases including both the re-reviewed cases and those reviewed only by the IRS Pathology committee. The 5-year survival rate of 24 children with alveolar RMS was 74% (p < .001). All five infants diagnosed to have an alveolar RMS died before the age of one. Two hundred and twenty-one patients (84%) had embryonal RMS. About three-fourths of the re-reviewed embryonal RMS tumors showed only minimal rhabdomyoblastic differentiation. Thirty-one had a spindle cell RMS, two were anaplastic variants. The 5-year survival rate for patients with embryonal RMS subtypes combined was 94%, and 97% for the 144 patients with poorly differentiated embryonal RMS. In contrast, 90 of 432 IRS II patients treated for poorly differentiated embryonal RMS located in extraocular sites had a 66% survival estimate.

Entities:  

Mesh:

Year:  1997        PMID: 9142207     DOI: 10.1002/(sici)1096-911x(199707)29:1<51::aid-mpo10>3.0.co;2-7

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  17 in total

Review 1.  [Current aspects of eyelid, lacrimal and orbital surgery in childhood].

Authors:  G Avgitidou; K R Koch; C Cursiefen; L M Heindl
Journal:  Ophthalmologe       Date:  2015-02       Impact factor: 1.059

2.  Association of T and N Categories of the American Joint Commission on Cancer, 8th Edition, With Metastasis and Survival in Patients With Orbital Sarcoma.

Authors:  Ho-Seok Sa; Maria Laura Rubin; Jing Ning; Wen Li; Michael T Tetzlaff; Susan L McGovern; Arnold C Paulino; Cynthia E Herzog; Jonathan B Gill; Bita Esmaeli
Journal:  JAMA Ophthalmol       Date:  2020-04-01       Impact factor: 7.389

3.  Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology Group.

Authors:  Lisa A Teot; Michaela Schneider; Aaron R Thorner; Jing Tian; Yueh-Yun Chi; Matthew Ducar; Ling Lin; Marcin Wlodarski; Holcombe E Grier; Christopher D M Fletcher; Paul van Hummelen; Stephen X Skapek; Douglas S Hawkins; Amy J Wagers; Carlos Rodriguez-Galindo; Simone Hettmer
Journal:  Cancer       Date:  2018-02-20       Impact factor: 6.860

4.  Primary ophthalmic rhabdomyosarcoma in 33 patients.

Authors:  C L Shields; J A Shields; S G Honavar; H Demirci
Journal:  Trans Am Ophthalmol Soc       Date:  2001

5.  45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  Ralph P Ermoian; John Breneman; David O Walterhouse; Yueh-Yun Chi; Jane Meza; James Anderson; Douglas S Hawkins; Andrea A Hayes-Jordan; David M Parham; Torunn I Yock; Sarah S Donaldson; Suzanne L Wolden
Journal:  Pediatr Blood Cancer       Date:  2017-05-26       Impact factor: 3.167

6.  Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III and -IV, 1984-1997: a report from the Children's Oncology Group.

Authors:  Beverly Raney; Winston Huh; Douglas Hawkins; Andrea Hayes-Jordan; Lynn Million; David Rodeberg; Lisa Teot; James Anderson
Journal:  Pediatr Blood Cancer       Date:  2012-09-07       Impact factor: 3.167

7.  Orbital sarcoma with metastases at diagnosis: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Authors:  Winston W Huh; James R Anderson; David Rodeberg; Lisa Teot; Torunn Yock; R Beverly Raney
Journal:  Pediatr Blood Cancer       Date:  2010-07-01       Impact factor: 3.167

8.  Embryonal rhabdomyosarcoma of the uterine corpus: a clinicopathological and molecular analysis of 21 cases highlighting a frequent association with DICER1 mutations.

Authors:  Jennifer A Bennett; Zehra Ordulu; Robert H Young; Andre Pinto; Koen Van de Vijver; Eike Burandt; Pankhuri Wanjari; Rajeev Shah; Leanne de Kock; William D Foulkes; W Glenn McCluggage; Lauren L Ritterhouse; Esther Oliva
Journal:  Mod Pathol       Date:  2021-05-20       Impact factor: 7.842

9.  Detection of bone metastases in initial staging of orbital embryonal rhabdomyosarcoma by fluorodeoxyglucose positron emission tomography/computed tomography.

Authors:  Pelin Ozcan Kara; Gonca Kara Gedik; Oktay Sari
Journal:  Mol Imaging Radionucl Ther       Date:  2011-04-01

10.  Mutations in Hedgehog pathway genes in fetal rhabdomyomas.

Authors:  Simone Hettmer; Lisa A Teot; Paul van Hummelen; Laura MacConaill; Roderick T Bronson; Claudia Dall'Osso; Junhao Mao; Andrew P McMahon; Peter J Gruber; Holcombe E Grier; Carlos Rodriguez-Galindo; Christopher D Fletcher; Amy J Wagers
Journal:  J Pathol       Date:  2013-09       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.